21 Oct ACG 2022 Annual Scientific Meeting, Charlotte, North Carolina

Close this search box.

Appointment Of Chief Financial Officer & Company Secretary

8 April, 2021

Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to advise that Mr. Nick Allan has accepted an offer of employment with the Resonance Health group as Chief Financial Officer & Company Secretary (“CFO & Co Sec”) commencing on 31 May 2021.

Mr. Allan has served as CFO & Co Sec of a number of ASX listed and private companies, including as CFO & Co Sec of Schrole Group Ltd, an ASX listed Software-as-a-Service (“SaaS”) technology and services company that provides software-driven solutions to organisations worldwide.

Mr. Allan has also worked as an analyst for JP Morgan (European M&A Division) and in the corporate advisory divisions of Ernst & Young and Deloitte Corporate Finance. He is experienced with corporate governance requirements and the ASX Listing Rules.

Mr. Allan’s appointment follows the resignation of Mr. Agha Shahzad who has been employed by Resonance Health for almost twelve years, the past three-and-a-half years of which he served as CFO & Co Sec of the Resonance Health group.

Alison Laws, Chief Executive Officer of Resonance Health said this of the changes:

“Agha has provided more than a decade of excellence in service to Resonance Health, culminating in the last three and a half years as CFO & Co Sec. Agha has had a continuous focus on the best interests of the Company and has been a key part in its transition. It has been an absolute pleasure working with him. The whole team at Resonance Health wishes Agha and his family all the best with his future endeavours. At the same time, we are very excited to welcome Nick Allan to our team. Nick’s experience as a CFO of public-listed and private companies and prior to that, as an analyst in corporate advisory in Big 4 firms and investment banking, is consistent with Resonance Health’s focus on commercial outcomes and accelerating growth from our existing suite of regulatory cleared products and from our exciting R&D pipeline”.

Mr. Mitchell Wells has been appointed as Company Secretary of Resonance Health and he will serve in this role until Mr. Allan’s commencement in the role on 31 May 2021. Mr. Wells already serves as a Director of Resonance Health and he provides consulting services to the Company. He has previously served as a Company Secretary of several ASX listed companies.

This announcement has been authorised by the Board of Directors of the Company.